Jardiance® (empagliflozin) – New indication
Boehringer Ingelheim and Eli Lilly announced the FDA approval of Jardiance (empagliflozin), to reduce the risk of cardiovascular (CV) death plus hospitalization for heart failure (HHF) in adults with heart failure and reduced ejection fraction.
Download PDF
